Clinical Trials Browser

Laryngeal Neoplasms × Specimen Handling × Clear all

NCT05063552 2026-03-18

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05172245 2026-03-18

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Phase 1 Recruiting

46 enrolled

Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05172258 2026-03-18

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Phase 2 Active not recruiting

52 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT06589804 2026-03-18

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Phase 3 Recruiting

158 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT07156227 2026-03-18

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

Phase 1 Not yet recruiting

39 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05136196 2026-03-17

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Phase 2 Recruiting

150 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Recruiting

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT07441681 2026-03-02

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Phase 3 Not yet recruiting

454 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05075980 2026-02-13

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

Phase 2 Recruiting

174 enrolled

Head & Neck

Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Lymphatic Metastasis, Mouth Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms, Salivary Gland Neoplasms

NCT06636734 2026-02-11

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Phase 2 Recruiting

28 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06532279 2026-02-02

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Phase 2 Recruiting

98 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Phase 1 Active not recruiting

7 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

NCT06084845 2024-07-25

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Phase 2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms